ALTHX THX Pharma Société Anonyme
THX Pharma Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for rare neurological disease, as well as TX01 for the treatment of Gaucher disease and Niemann-Pick type C diseases. The company was formerly known as Theranexus Société Anonyme and change its name to THX Pharma Société Anonyme in September 2025. The company was founded in 2013 and is headquartered in Lyon, France.…
Industry Peers
BiotechnologyKey Statistics
About THX Pharma (EPA: ALTHX)
›
THX Pharma (EPA: ALTHX) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 12 employees.
The shares were at 3.220 EUR on 19 November 2026, up 92.2% over 52 weeks. Its 52-week range is 1.490 EUR to 5.100 EUR: the price is 36.9% below the high and 116.1% above the low.
Its market capitalisation is 46.65M EUR.
THX Pharma reports return on equity of -103.5%, an operating margin of -112.0% and revenue up 303.9% year over year.
It holds more cash than debt, a net cash position of 14.86M EUR. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. One analyst covers the stock; their mean price target of 5.800 EUR is 80.1% above the current price.